Project Details
Description
Dr. Tae-Wan Kim and colleagues have identified an 'atypical monoamine transporter' as a novel therapeutic target in Alzheimer's disease. The proposed research is designed to further validate the new target and generate therapeutic lead compounds. Further research will be conducted to understand this target in greater depth, using cell biological approaches.
Status | Finished |
---|---|
Effective start/end date | 7/1/12 → 6/30/14 |
Funding
- BrightFocus Foundation: US$150,000.00
ASJC Scopus Subject Areas
- Clinical Neurology
- Neurology
- Medicine(all)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.